Taxol Ruling Re-Emphasizes “Ministerial” Role For FDA On Patents
Executive Summary
The Taxol appeals court ruling may make it more difficult for FDA to stray from a "ministerial" approach to "Orange Book" patent listings
You may also be interested in...
BuSpar Antitrust Settlement Is Two-Times Sales During Extended Patent Life
Bristol-Myers Squibb's proposed $535 mil. payment to settle BuSpar antitrust litigation amounts to more than twice the sales of the anxiety drug during the four months of extended exclusivity for the product that prompted the suits
BuSpar Antitrust Settlement Is Two-Times Sales During Extended Patent Life
Bristol-Myers Squibb's proposed $535 mil. payment to settle BuSpar antitrust litigation amounts to more than twice the sales of the anxiety drug during the four months of extended exclusivity for the product that prompted the suits
ANDA Approvals In 2002 Could Affect Over $10 Bil. In Brand Sales
Branded products representing more than $10 bil. in annual sales are vulnerable to first generic competition in 2002